A primary reason why potential anticancer drugs fail in clinical trials is the limitations of existing in vitro screening systems. The purpose of in vitro testing is to aid in the selection of efficacious compounds from a range of candidates with variable levels of the desired properties. In vitro cell-culture tumor models are the most widely used screening systems, however, they lack the complexity of the natural microenvironment of the host organism. Clearly, an effective screening system should possess qualities and organization similar to those of a natural tumor microenvironment. In an attempt to better simulate a tumor and its microenvironment sophisticated models have been developed, such as the three-dimensional cultures. In additio...
Cancer is one of the major life threatening diseases worldwide. The available anticancer drugs have ...
Today, innovative three-dimensional (3D) cell culture models have been proposed as viable and biomim...
High attrition of new oncology drug candidates in clinical trials is partially caused by the poor pr...
A primary reason why potential anticancer drugs fail in clinical trials is the limitations of existi...
A primary reason why potential anticancer drugs fail in clinical trials is the limitations of existi...
A primary reason why potential anticancer drugs fail in clinical trials is the limitations of existi...
One of the reasons for the failure of potential anticancer drugs in clinical trials is the imperfect...
One of the reasons for the failure of potential anticancer drugs in clinical trials is the imperfect...
One of the reasons for the failure of potential anticancer drugs in clinical trials is the imperfect...
The development of new high-tech systems for screening anticancer drugs is one of the main problems ...
© Copyright © 2020 Kitaeva, Rutland, Rizvanov and Solovyeva. The development of new high-tech system...
The study of the development of anti-cancer drugs and preclinical efficacy tests has until today enc...
Three-dimensional (3D) cultures are becoming increasingly popular due to their ability to mimic tiss...
Over the past few years, establishment and adaptation of cell-based assays for drug development and ...
Preclinical screening of medicinal drugs for novel anti-cancer treatments faces a problem of a ratio...
Cancer is one of the major life threatening diseases worldwide. The available anticancer drugs have ...
Today, innovative three-dimensional (3D) cell culture models have been proposed as viable and biomim...
High attrition of new oncology drug candidates in clinical trials is partially caused by the poor pr...
A primary reason why potential anticancer drugs fail in clinical trials is the limitations of existi...
A primary reason why potential anticancer drugs fail in clinical trials is the limitations of existi...
A primary reason why potential anticancer drugs fail in clinical trials is the limitations of existi...
One of the reasons for the failure of potential anticancer drugs in clinical trials is the imperfect...
One of the reasons for the failure of potential anticancer drugs in clinical trials is the imperfect...
One of the reasons for the failure of potential anticancer drugs in clinical trials is the imperfect...
The development of new high-tech systems for screening anticancer drugs is one of the main problems ...
© Copyright © 2020 Kitaeva, Rutland, Rizvanov and Solovyeva. The development of new high-tech system...
The study of the development of anti-cancer drugs and preclinical efficacy tests has until today enc...
Three-dimensional (3D) cultures are becoming increasingly popular due to their ability to mimic tiss...
Over the past few years, establishment and adaptation of cell-based assays for drug development and ...
Preclinical screening of medicinal drugs for novel anti-cancer treatments faces a problem of a ratio...
Cancer is one of the major life threatening diseases worldwide. The available anticancer drugs have ...
Today, innovative three-dimensional (3D) cell culture models have been proposed as viable and biomim...
High attrition of new oncology drug candidates in clinical trials is partially caused by the poor pr...